| Date | Acquired company | Acquiring company | Amount | Related |
|---|---|---|---|---|
| 2015-06-29 | Emory Genetics Laboratory (USA - GA) | Eurofins Scientific (Luxemburg) | $ 40 million (€ 36.44 million) | |
| 2015-06-17 | Bio-Access (France) | Eurofins Scientific (Luxembourg) | € 150 million | Clinical diagnostic Medical biology |
| 2015-06-10 | Bayer\'s Diabetes Care business (Germany) | Panasonic Healthcare Holdings (Japan) | € 1.022 billion | Metabolic diseases Medical devices |
| 2015-06-02 | X-Body (USA - MA) | Juno Therapeutics (USA - WA) | $ 21 million and success-based payments | cell therapy |
| 2015-06-01 | Auden Mckenzie (UK) | Actavis (Ireland) | £306 million (€427 million) plus a two-year royalty on a percentage of gross profits of one of Auden Mckenzie\'s products | Generic drugs |
| 2015-06-01 | Diatherix Laboratories (USA - AL) | Eurofins Scientific (Luxembourg) | $ 50 million (€ 45.63 million) | |
| 2015-05-28 | J&J Cordis business (USA - NJ) | Cardinal Health (USA - OH) | $2 billion | Cardiovascular diseases Medical devices |
| 2015-05-26 | Pharmacyclics (USA - CA) | AbbVie (USA - IL) | $21 billion | Cancer - Oncology |
| 2015-05-19 | OctreoPharm Sciences (Germany) | Ipsen (France) | up to €50 million | Cancer - Oncology - Rare diseases |
| 2015-05-18 | Biostatem (France) | Axonal (France) | undisclosed | CRO |
| 2015-05-15 | Prosonix (UK) | Circassia Pharmaceuticals (UK) | up to £100 million (up to € 138,3 million) | Allergic diseases - Inflammatory diseases - Respiratory diseases |
| 2015-05-15 | Aerocrine (Sweden) | Circassia Pharmaceuticals (UK) | SEK 1.78 billion (approximately £139 million) | Allergic diseases - Inflammatory diseases - Respiratory diseases |
| 2015-05-12 | minority interest in AM-Pharma (The Netherlands) | Pfizer (USA - NY) | $87.5 million and up to $512.5 million upon option exercise | Autoimmune diseases - Inflammatory diseases - Kidney diseases - Renal diseases |
| 2015-05-11 | more than 15 biologic development programs from Selexis (Switzerland) | Ligand Pharmaceuticals (USA - CA) | $4 million (€3.57 million) | |
| 2015-05-11 | Stage Cell Therapeutics (Germany) | Juno Therapeutics (USA - CA) | €52.5 Million in cash ($59 Million) and 486,279 Shares of Juno Stock | Cell therapy Manufacturing - Production |
| 2015-05-07 | Lanthio Pharma (The Netherlands) | MorphoSys (Germany) | € 20 million | Cardiovascular diseases - Cerebrovascular diseases - Metabolic diseases - Neurodegenerative diseases |
| 2015-05-06 | Synageva BioPharma (USA - MA) | Alexion Pharmaceuticals (USA - CT) | $8.4 billion (€7.52 billion) | Rare diseases |
| 2015-05-05 | EirGen Pharma (Ireland) | Opko Health (USA - FL) | $ 135 million | |
| 2015-04-27 | Quanticel Pharmaceuticals (USA - CA) | Celgene (USA _ NJ) | up to $485 million | Cancer - Oncology |
| 2015-04-24 | Idis Group (UK) | Clinigen (UK) | £225 million | CRO - Technology - Services |
